Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo

Radka Stoyanova, Paul Hachem, Harvey Hensley, Li Yan Khor, Zhaomei Mu, M. Elizabeth H Hammond, Sudhir Agrawal, Alan Pollack

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model. Methods: Androgen-sensitive LNCaP cells were grown in the prostates of nude mice. Magnetic resonance imaging-based tumor volume and serum prostate-specific antigen (PSA) measurements were used to assess effects on tumor response. Tumor response was measured by biochemical and tumor volume failure definitions and doubling time estimates from fitted PSA and tumor volume growth curves. Expression of MDM2, p53, p21, and Ki-67 was quantified using immunohistochemical staining and image analysis of formalin-fixed tissue, analogous to methods used clinically. Results: Antisense-MDM2 significantly inhibited the growth of LNCaP tumors over the mismatch controls. The most significant increase in tumor growth delay and tumor doubling time was from AS-MDM2 + AD + RT, although the effect of AS-MDM2 + AD was substantial. Expression of MDM2 was significantly reduced by AS-MDM2 in the setting of RT. Conclusions: This is the first in vivo investigation of the effects of AS-MDM2 in an orthotopic model and the first to demonstrate incremental sensitization when added to AD and AD + RT. The results with AD underscore the potential to affect micrometastatic disease, which is probably responsible for treatment failure in 30-40% of men with high-risk disease.

Original languageEnglish
Pages (from-to)1151-1160
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume68
Issue number4
DOIs
StatePublished - Jul 15 2007
Externally publishedYes

Fingerprint

deprivation
Androgens
Prostatic Neoplasms
tumors
cancer
Radiation
radiation therapy
radiation
Radiotherapy
Tumor Burden
antigens
Neoplasms
Prostate-Specific Antigen
Growth
staining
cells
Treatment Failure
image analysis
Nude Mice
serums

Keywords

  • Antisense-MDM2
  • In vivo tumor model
  • MRI
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo. / Stoyanova, Radka; Hachem, Paul; Hensley, Harvey; Khor, Li Yan; Mu, Zhaomei; Hammond, M. Elizabeth H; Agrawal, Sudhir; Pollack, Alan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 68, No. 4, 15.07.2007, p. 1151-1160.

Research output: Contribution to journalArticle

Stoyanova, Radka ; Hachem, Paul ; Hensley, Harvey ; Khor, Li Yan ; Mu, Zhaomei ; Hammond, M. Elizabeth H ; Agrawal, Sudhir ; Pollack, Alan. / Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 68, No. 4. pp. 1151-1160.
@article{c9a2330d9cab497ab60fb3859dcdea79,
title = "Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo",
abstract = "Purpose: To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model. Methods: Androgen-sensitive LNCaP cells were grown in the prostates of nude mice. Magnetic resonance imaging-based tumor volume and serum prostate-specific antigen (PSA) measurements were used to assess effects on tumor response. Tumor response was measured by biochemical and tumor volume failure definitions and doubling time estimates from fitted PSA and tumor volume growth curves. Expression of MDM2, p53, p21, and Ki-67 was quantified using immunohistochemical staining and image analysis of formalin-fixed tissue, analogous to methods used clinically. Results: Antisense-MDM2 significantly inhibited the growth of LNCaP tumors over the mismatch controls. The most significant increase in tumor growth delay and tumor doubling time was from AS-MDM2 + AD + RT, although the effect of AS-MDM2 + AD was substantial. Expression of MDM2 was significantly reduced by AS-MDM2 in the setting of RT. Conclusions: This is the first in vivo investigation of the effects of AS-MDM2 in an orthotopic model and the first to demonstrate incremental sensitization when added to AD and AD + RT. The results with AD underscore the potential to affect micrometastatic disease, which is probably responsible for treatment failure in 30-40{\%} of men with high-risk disease.",
keywords = "Antisense-MDM2, In vivo tumor model, MRI, Prostate cancer, Radiation",
author = "Radka Stoyanova and Paul Hachem and Harvey Hensley and Khor, {Li Yan} and Zhaomei Mu and Hammond, {M. Elizabeth H} and Sudhir Agrawal and Alan Pollack",
year = "2007",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2007.03.047",
language = "English",
volume = "68",
pages = "1151--1160",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo

AU - Stoyanova, Radka

AU - Hachem, Paul

AU - Hensley, Harvey

AU - Khor, Li Yan

AU - Mu, Zhaomei

AU - Hammond, M. Elizabeth H

AU - Agrawal, Sudhir

AU - Pollack, Alan

PY - 2007/7/15

Y1 - 2007/7/15

N2 - Purpose: To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model. Methods: Androgen-sensitive LNCaP cells were grown in the prostates of nude mice. Magnetic resonance imaging-based tumor volume and serum prostate-specific antigen (PSA) measurements were used to assess effects on tumor response. Tumor response was measured by biochemical and tumor volume failure definitions and doubling time estimates from fitted PSA and tumor volume growth curves. Expression of MDM2, p53, p21, and Ki-67 was quantified using immunohistochemical staining and image analysis of formalin-fixed tissue, analogous to methods used clinically. Results: Antisense-MDM2 significantly inhibited the growth of LNCaP tumors over the mismatch controls. The most significant increase in tumor growth delay and tumor doubling time was from AS-MDM2 + AD + RT, although the effect of AS-MDM2 + AD was substantial. Expression of MDM2 was significantly reduced by AS-MDM2 in the setting of RT. Conclusions: This is the first in vivo investigation of the effects of AS-MDM2 in an orthotopic model and the first to demonstrate incremental sensitization when added to AD and AD + RT. The results with AD underscore the potential to affect micrometastatic disease, which is probably responsible for treatment failure in 30-40% of men with high-risk disease.

AB - Purpose: To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model. Methods: Androgen-sensitive LNCaP cells were grown in the prostates of nude mice. Magnetic resonance imaging-based tumor volume and serum prostate-specific antigen (PSA) measurements were used to assess effects on tumor response. Tumor response was measured by biochemical and tumor volume failure definitions and doubling time estimates from fitted PSA and tumor volume growth curves. Expression of MDM2, p53, p21, and Ki-67 was quantified using immunohistochemical staining and image analysis of formalin-fixed tissue, analogous to methods used clinically. Results: Antisense-MDM2 significantly inhibited the growth of LNCaP tumors over the mismatch controls. The most significant increase in tumor growth delay and tumor doubling time was from AS-MDM2 + AD + RT, although the effect of AS-MDM2 + AD was substantial. Expression of MDM2 was significantly reduced by AS-MDM2 in the setting of RT. Conclusions: This is the first in vivo investigation of the effects of AS-MDM2 in an orthotopic model and the first to demonstrate incremental sensitization when added to AD and AD + RT. The results with AD underscore the potential to affect micrometastatic disease, which is probably responsible for treatment failure in 30-40% of men with high-risk disease.

KW - Antisense-MDM2

KW - In vivo tumor model

KW - MRI

KW - Prostate cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=34447304367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447304367&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.03.047

DO - 10.1016/j.ijrobp.2007.03.047

M3 - Article

C2 - 17637390

AN - SCOPUS:34447304367

VL - 68

SP - 1151

EP - 1160

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -